Condition or Therapy:

Atypical teratoid rhabdoid tumors (AT/RT); malignant rhabdoid tumors (MRT)

Category:

Cancer and Blood Disorders

Study Number: SC-9010

What is the goal of this study?

The main goal of this study is to find out what effects the experimental study drug, alisertib has when it's added to chemotherapy and radiation for children who have been recently diagnosed with atypical teratoid rhabdoid tumors (AT/RT).

The title of this study is called "Phase 2 Study of Alisertib as a Single Agent in Recurrent and Refractory Central Nervous System Atypical Teratoid Rhabdoid Tumors (AT/RT) and Extra-CNS Malignant Rhabdoid Tumors (MRT) and in Combination Therapy in Newly Diagnosed ATRT (SJATRT)."

Who can join the study?

This study might be a good fit for children and young adults who:

  • Are younger than 22 years of age
  • Have histologic diagnosis of AT/RT or malignant rhabdoid tumors (MRT) as documented by the institutional pathologist with loss of INI1 or BRG1 expression in tumor cells confirmed by immunohistochemistry, or by molecular confirmation.

Researchers use many other factors to decide whether a patient can take part in a study (inclusion criteria) or cannot take part (exclusion criteria). The study team at Seattle Children’s can explain what these factors mean for you or your child.

What will happen if my child takes part in this study?

You can read more about this study at clinicaltrials.gov.

Who can I contact for more information?

To learn more, call 206-987-2106 or send us an email.


Study Location(s):

Seattle Children’s Hospital main campus

Principal Investigator:

Dr. Sarah Leary